UNITEFA   23945
UNIDAD DE INVESTIGACION Y DESARROLLO EN TECNOLOGIA FARMACEUTICA
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
Evaluation of the addictive potential of morphine in a place preference conditioned model in rats pretreated with omega 3 fatty acids
Autor/es:
MANZO RUBEN HILARIO; CANCELA LILIANA MARINA; GUZMAN ANDREA; LAINO CARLOS HORACIO; ROMAÑUK CAROLINA BEATRIZ; OLIVERA MARIA EUGENIA
Lugar:
Buenos Aires
Reunión:
Congreso; 76th World Congress of Pharmacy & Pharmaceutical Sciences, International Pharmaceutical Federation (FIP); 2016
Institución organizadora:
International Pharmaceutical Federation (FIP)
Resumen:
INTRODUCTION. Oral administration of a new pharmaceutical composition (Argentine Patent Application P20120100854) which combines morphine and omega-3 fatty acids (MOR:O3) presents a analgesic synergistic effect in rats pre-treated with O3. The interaction of MOR with brain receptors associated with pain and mechanisms of brain reward is related to the addictive potential of MOR inducing conditioned place preference (CPP).OBJECTIVE. Assess whether pretreatment with O3 has a facilitating effect of the reinforcing properties of MOR when it is administered as MOR:O3.METHODOLOGY. Wistar rats were assigned to two experimental groups pre-treated with O3 or saline (control group). Both groups were then conditioned with MOR:O3 (MOR at doses of 12 and 24 mg/kg) for 8 days in a CPP apparatus.RESULTS AND DISCUSSION. In groups pretreated with O3 or saline an induction of MOR conditioned preference was observed at both doses.However, no differences in conditioning were observed between the groups pre-treated with O3 or saline suggesting that O3 does not potentiate the reinforcing properties of MOR when administered as MOR:O3.CONCLUSIONS. The synergistic analgesic effect MOR:O3 does not increase the addictive potential of MOR. This finding is important mainly in patients with chronic pain and represents a novel therapeutic approach with a better response and less adverse effects associated with treatment with MOR.